Advertisement

Breast Cancer Research and Treatment

, Volume 114, Issue 3, pp 527–535 | Cite as

Time-varying pattern of recurrence risk for Chinese breast cancer patients

  • Wenjin Yin
  • Genhong Di
  • Liheng Zhou
  • Jinsong LuEmail author
  • Guangyu Liu
  • Jiong Wu
  • Kunwei Shen
  • Qixia Han
  • Zhenzhou Shen
  • Zhimin Shao
Epidemiology

Abstract

Purpose To analyze the rule of recurrence risk for breast cancer patients after surgery in order to get characteristics for Chinese breast cancer. Methods We performed a retrospective study of 2,213 female unilateral breast cancer patients undergoing surgery in Cancer hospital of Fudan University, Shanghai, China. Survival curves were performed with Kaplan–Meier method and annual recurrence hazard was estimated by hazard function. Results Annual recurrence hazard curve for entire population showed a double-peaked pattern, with a first major recurrence surge reaching the maximum at the second year after surgery and a second recurrence peak near the 9.5th year. The analysis according to tumor size, axillary lymph node (ALN) status (T1 + T2 versus T3, node-positive versus node-negative) and menopausal status as well as hormone receptor (HR) status proved that the double-peaked pattern was present in each subgroup. Compared with ER-positive tumors, ER-negative breast cancers were more likely to recur early. As far as Her-2/neu status was concerned, Her-2/neu-positive patients exhibited a relatively pronounced and variable pattern and tended to have more relapse across all time periods (P < 0.05). Conclusions The double-peaked pattern observed in our patients gives further support to tumor dormancy hypothesis. It contributes to different treatment strategies (e.g. the type and timing of adjuvant therapy) for different patients, which provide the possibility to improve survival.

Keywords

Breast neoplasm Recurrence hazard Tumor dormancy 

References

  1. 1.
    Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRefGoogle Scholar
  2. 2.
    Weiss RB, Woolf SH, Demakos E et al (2003) Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol 21:1825–1835PubMedCrossRefGoogle Scholar
  3. 3.
    Kimura M, Yanagita Y, Fujisawa T et al (2007) Study of time-course changes in annual recurrence rates for breast cancer: data analysis of 2,209 patients for 10 years post-surgery. Breast Cancer Res Treat 106:407–411PubMedCrossRefGoogle Scholar
  4. 4.
    Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMedGoogle Scholar
  5. 5.
    Brackstone M, Townson JL, Chambers AF (2007) Tumour dormancy in breast cancer: an update. Breast Cancer Res 9:208PubMedCrossRefGoogle Scholar
  6. 6.
    Simes RJ, Zelen M (1985) Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator’s primer. J Clin Oncol 3:1418–1431PubMedGoogle Scholar
  7. 7.
    Karrison TG, Ferguson DJ, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91:80–85PubMedCrossRefGoogle Scholar
  8. 8.
    Gasparini G, Biganzoli E, Bonoldi E et al (2001) Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat 65:71–75PubMedCrossRefGoogle Scholar
  9. 9.
    Demicheli R, Abbattista A, Miceli R et al (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41:177–185PubMedCrossRefGoogle Scholar
  10. 10.
    Demicheli R, Miceli R, Valagussa P et al (2000) Re: dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 92:347–348PubMedCrossRefGoogle Scholar
  11. 11.
    Demicheli R, Bonadonna G, Valagussa P et al (2005) Comment to Jatoi et al. report. Breast Cancer Res Treat 93:1–2Google Scholar
  12. 12.
    Yakovlev AY, Tsodikov AD, Boucher K et al (1999) The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer 85:1789–1798PubMedCrossRefGoogle Scholar
  13. 13.
    Jatoi I, Tsimelzon A, Weiss H et al (2005) Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89:173–178PubMedCrossRefGoogle Scholar
  14. 14.
    Baum M, Demicheli R, Hrushesky W et al (2005) Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer 41:508–515PubMedCrossRefGoogle Scholar
  15. 15.
    Demicheli R, Miceli R, Brambilla C et al (1999) Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’. Breast Cancer Res Treat 53:209–215PubMedCrossRefGoogle Scholar
  16. 16.
    Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271PubMedCrossRefGoogle Scholar
  17. 17.
    Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMedCrossRefGoogle Scholar
  18. 18.
    Demicheli R, Miceli R, Moliterni A et al (2005) Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 16:1449–1457PubMedCrossRefGoogle Scholar
  19. 19.
    Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846PubMedCrossRefGoogle Scholar
  20. 20.
    McShane LM, Altman DG, Sauerbrei W et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRefGoogle Scholar
  21. 21.
    Tamoxifen, Arimidex, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53PubMedCrossRefGoogle Scholar
  22. 22.
    Demicheli R (2001) Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 11:297–306PubMedCrossRefGoogle Scholar
  23. 23.
    Demicheli R, Retsky MW, Swartzendruber DE et al (1997) Proposal for a new model of breast cancer metastatic development. Ann Oncol 8:1075–1080PubMedCrossRefGoogle Scholar
  24. 24.
    Hilsenbeck SG, Ravdin PM, de Moor CA et al (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227–237PubMedCrossRefGoogle Scholar
  25. 25.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  26. 26.
    Peto R, Davies C, on Behalf of the ATLAS Collaboration (2007) ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women – preliminary results. Paper presented at the 30th annual San Antonio breast cancer symposium, Henry B. Gonzalez Convention Center, San Antonio, Texas, USA, 13–16 December 2007Google Scholar
  27. 27.
    Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRefGoogle Scholar
  28. 28.
    Gusterson BA, Gelber RD, Goldhirsch A et al (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049–1056PubMedGoogle Scholar
  29. 29.
    Bull SB, Ozcelik H, Pinnaduwage D et al (2004) The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 22:86–96PubMedCrossRefGoogle Scholar
  30. 30.
    Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Paper presented at the 28th San Antonio breast cancer symposium, Henry B. Gonzalez Convention Center, San Antonio, Texas, USA, 8–11 December 2005Google Scholar
  31. 31.
    Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36PubMedCrossRefGoogle Scholar
  32. 32.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRefGoogle Scholar
  33. 33.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820PubMedCrossRefGoogle Scholar
  34. 34.
    Slamon D, Eiermann W, Robert N et al (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Paper presented at the 29th San Antonio breast cancer symposium, Henry B. Gonzalez Convention Center, San Antonio, Texas, USA, 14–17 December 2006Google Scholar
  35. 35.
    Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Wenjin Yin
    • 1
    • 2
  • Genhong Di
    • 1
    • 2
  • Liheng Zhou
    • 1
    • 2
  • Jinsong Lu
    • 1
    • 2
    Email author
  • Guangyu Liu
    • 1
    • 2
  • Jiong Wu
    • 1
    • 2
  • Kunwei Shen
    • 1
    • 2
  • Qixia Han
    • 1
    • 2
  • Zhenzhou Shen
    • 1
    • 2
  • Zhimin Shao
    • 1
    • 2
  1. 1.Department of Breast Surgery, Cancer Hospital/Cancer InstituteFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations